How Biotechs Survive Despite Volatile Capital Markets
Law360, New York (March 30, 2016, 3:23 PM EDT) -- Early-stage and midstage biotechs often rely on the public markets to raise the capital necessary to fund ongoing research and development, but the recent wave of market volatility has stalled the once-hot initial public offering pipeline and depressed valuations, forcing many to opt for alternatives like collaborations, mergers and acquisitions to survive, experts say.
While August saw some market volatility, it registered as a minor bump in the road in an otherwise generally strong year in the U.S. public markets. The same has not held true for the rocky start to 2016. Falling oil prices, uncertainty about interest rates and the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!